Biotechnology News and Research

RSS

Takeda receives Japanese approval for additional indications for NESINA

Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited's applications for two additional indications for "NESINA®" (alogliptin), combination therapy with sulfonylurea and combination therapy with biguanide for type 2 diabetes, were approved by the Japanese Ministry of Health, Labour and Welfare.

25 Feb 2011

New study discloses mechanism controlling Rb2/p130 gene expression in lung cancer cells

Despite innumerable studies on lung cancer, many aspects of the disease have yet to be understood, including the role played by the retinoblastoma-related protein Rb2/p130 in the evolution of the disease.

25 Feb 2011

Targets against MRSA in microgravity

NASA astronauts onboard Space Shuttle Discovery's final mission to the International Space Station (ISS) will carry out the eleventh scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. The research on STS-133 will focus on changes that occur to methicillin-resistant Staphylococcus aureus (MRSA) in microgravity, which can be targeted to create new vaccines and therapeutics.

25 Feb 2011

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix BioTherapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease. Taliglucerase alfa is a plant-cell expressed form of glucocerebrosidase (GCD).

25 Feb 2011

Harvard Bioscience fourth quarter revenues increase 6.8% to $1.9 million

Harvard Bioscience, Inc., a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial highlights for the fourth quarter and full year ended December 31, 2010.

From Harvard Bioscience 25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Collision of fast and slow protein-trains cause major DNA derailment

Scientists have published results that will forever change the way researchers view the interplay between gene expression, DNA replication and the prevention of DNA damage.

25 Feb 2011

LinkMed reports fourth quarter net sales of SEK 20.0 million

LinkMed AB: Net sales for the year were SEK 80.5 million. Currency effects had a negative impact on sales of SEK 8 million for the year.

25 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

BioCryst Pharmaceuticals, Inc. announced that it has been awarded a $55.0 million contract modification by the U.S. Department of Health & Human Services intended to fund to completion the Phase 3 development of its neuraminidase inhibitor, intravenous peramivir, for the treatment of patients hospitalized with influenza.

25 Feb 2011

Celgene, Elan enter settlement and license agreement for ABRAXANE

Elan Corporation plc and Celgene Corporation, today announced that Elan subsidiary Elan PharmaInternational Limited has entered into a settlement and license agreement with Celgene Corporation resolving the patent infringement litigation involving ABRAXANE.

24 Feb 2011

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

PhRMA: 460 medicines in development for rare diseases

America's biopharmaceutical research companies are intensifying research into rare diseases, which often are among the most devastating to patients and complex for researchers. A record 460 medicines for rare diseases are in late stages of the pipeline, either in clinical trials or awaiting Food and Drug Administration (FDA) review, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

24 Feb 2011

Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

Generex Biotechnology Corporation announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration Expanded Access Treatment Investigational New Drug Program for Generex Oral-lyn, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.

24 Feb 2011

ProtoKinetix demonstrates ability of AAGP molecules against inflammatory diseases

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known.

24 Feb 2011

Biomatrica announces strategic partnership agreement with In-Q-Tel

Biomatrica, Inc., a leader in room temperature biostability technology, today announced a strategic partnership agreement with In-Q-Tel. IQT is the independent, strategic investment firm that identifies innovative technology solutions to support the mission of the U.S. Intelligence Community.

24 Feb 2011

Oncolytics completes patient enrollment in REOLYSIN trial to treat metastatic colorectal cancer

Oncolytics Biotech Inc. announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases.

23 Feb 2011

ACT receives patent for its single-blastomere technology

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent on its "single-blastomere" technique. Patent Number 7,893,315 broadly covers ACT's proprietary single-blastomere technology that provides a non-destructive alternative for deriving human embryonic stem cell lines.

23 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

Signaling mechanism in bacterial ribosome linked to antibiotic resistance

Researchers at the University of Illinois at Chicago have discovered a signaling mechanism in the bacterial ribosome that detects proteins that activate genes for antibiotic resistance.

23 Feb 2011

Biotechnology News and Research

Takeda receives Japanese approval for additional indications for NESINA

New study discloses mechanism controlling Rb2/p130 gene expression in lung cancer cells

Targets against MRSA in microgravity

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Harvard Bioscience fourth quarter revenues increase 6.8% to $1.9 million

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Collision of fast and slow protein-trains cause major DNA derailment

LinkMed reports fourth quarter net sales of SEK 20.0 million

Genentech granted FDA hearing on Avastin for metastatic breast cancer

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

Celgene, Elan enter settlement and license agreement for ABRAXANE

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PhRMA: 460 medicines in development for rare diseases

Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

ProtoKinetix demonstrates ability of AAGP molecules against inflammatory diseases

Biomatrica announces strategic partnership agreement with In-Q-Tel

Oncolytics completes patient enrollment in REOLYSIN trial to treat metastatic colorectal cancer

ACT receives patent for its single-blastomere technology

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Signaling mechanism in bacterial ribosome linked to antibiotic resistance

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News